Factors correlating to the propensity of general practitioners to substitute borderline vitamin B12 deficiency by Cham, Grace et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=ipri20
Scandinavian Journal of Primary Health Care
ISSN: 0281-3432 (Print) 1502-7724 (Online) Journal homepage: https://www.tandfonline.com/loi/ipri20
Factors correlating to the propensity of general
practitioners to substitute borderline vitamin B12
deficiency
Grace Cham, Nichola Davis, Edward Strivens, Aileen Traves, Grant
Manypeney & Ronny Gunnarsson
To cite this article: Grace Cham, Nichola Davis, Edward Strivens, Aileen Traves, Grant
Manypeney & Ronny Gunnarsson (2018) Factors correlating to the propensity of general
practitioners to substitute borderline vitamin B12 deficiency, Scandinavian Journal of Primary
Health Care, 36:3, 242-248, DOI: 10.1080/02813432.2018.1487522
To link to this article:  https://doi.org/10.1080/02813432.2018.1487522
© 2018 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
Published online: 22 Jun 2018.
Submit your article to this journal 
Article views: 282
View Crossmark data
RESEARCH ARTICLE
Factors correlating to the propensity of general practitioners to substitute
borderline vitamin B12 deficiency
Grace Chama, Nichola Davisa, Edward Strivensa,b, Aileen Travesa, Grant Manypeneyc and
Ronny Gunnarssona,d,e
aCairns Clinical School, College of Medicine and Dentistry, James Cook University, Australia; bOlder Persons and Subacute Services,
Cairns and Hinterland Hospital and Health Service, Cairns, Queensland, Australia; cMareeba Medical Clinic, Queensland, Australia;
dResearch and Development Unit, Primary Health Care and Dental Care, Southern €Alvsborg County, N€arhalsan, V€astra G€otaland
Region, Sweden; eDepartment of Public Health and Community Medicine, Institute of Medicine, The Sahlgrenska Academy, University
of Gothenburg, Sweden
ABSTRACT
Objective: This study aims to identify factors which correlate to the propensity of general practi-
tioners (GPs) to prescribe supplementation for borderline vitamin B12 deficiency.
Design: Cross-sectional surveys were distributed in person.
Setting: Conferences held in Cairns, Palm Cove Beach, Mt Isa; educational meetings in Atherton;
and meetings with individual general practices within the Cairns and Hinterland region. All
located in Queensland, Australia.
Subjects: 128 practicing GP specialists and registrars (practitioners in training).
Main outcome measures: Responses to the Likert scale statements with its five options scaling
from ‘strongly disagree’ to ‘strongly agree’ were recoded to have binary outcomes for analysis.
Results: A survey response rate of 89% was achieved. Participants who felt patient demands
influence the management of borderline vitamin B12 deficiency were more likely to prescribe
supplementation (OR 2.4, p¼ 0.037). Participants who perceived an overuse of vitamin B12 were
less likely to prescribe B12 (OR 0.39, p¼ 0.019). Participants who often saw patients with vitamin
B12 deficiency were less likely to request for the complementary biomarkers plasma methylma-
lonic acid or total homocysteine (OR 0.41, p¼ 0.045).
Conclusions: The identified disparity to prescribe vitamin B12 for borderline deficiency may be
described as an attempt in the GP collective to seek a balance between being the patient’s or
the society’s doctor. We propose that relevant authorities try to reduce this disparity by describ-
ing a management strategy for borderline vitamin B12 deficiency.
KEY POINTS
 General practitioners hold different thresholds for commencing supplementation in cases of
borderline vitamin B12 deficiency.
 Participants from Australia were asked to fill out a cross-sectional survey to explore factors
which correlate with the propensity to prescribe in clinical practice.
 Our study identified that patient demands and a practitioner’s perception of whether there is
an overuse of vitamin B12 in the community influenced the propensity to treat for deficiency.
 The results give insight into reasons for initiating supplementation, and will help inform gen-
eral practitioners on their current management.
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Background
Vitamin B12 deficiency is a public health issue.
Although the true prevalence of vitamin B12 defi-
ciency within most populations remains unknown, fig-
ures for low serum vitamin B12 are reported up to
23% within the elderly population [1–3]. Other risk
groups commonly affected include vegans and vegeta-
rians, individuals of South-Asian heritage, patients with
pernicious anaemia or a malabsorption syndrome,
those who have undergone gastric surgery and users
of metformin, psychotropic drugs or gastric acid-block-
ing agents [4–10].
CONTACT Grace Cham grace.cham@my.jcu.edu.au Cairns Clinical School, College of Medicine and Dentistry, James Cook University, Australia
 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE
2018, VOL. 36, NO. 3, 242–248
https://doi.org/10.1080/02813432.2018.1487522
Vitamin B12 deficiency is defined by characteristic
clinical features which respond to supplementation. As
the condition has an insidious onset which can mani-
fest with an array of non-specific haematologic and/or
neuropsychiatric signs and symptoms, vitamin B12
deficiency can be a difficult diagnosis. Very low levels
of serum B12 (such as below 100pmol/L) is considered
to represent deficiency by most practitioners. Markedly
elevated values of serum B12 (such as above
350 pmol/L) are taken to indicate the absence of defi-
ciency, and symptoms are likely attributed to other
conditions. There is however no internationally
accepted consensus on the upper and lower limits for
serum vitamin B12 levels [11].
The value of newer biomarkers, such as plasma
methylmalonic acid and total homocysteine, over the
total serum B12 assay in diagnosis is contentious.
Evidence in the form of randomized controlled trials is
lacking, and few international guidelines on the man-
agement of vitamin B12 deficiency have been pub-
lished [12–14]. Guidelines released by The British
Committee for Standards in Haematology state that
serum B12 should be followed up by second-line
methylmalonic acid to clarify uncertainties [14].
However, the latter test is not readily available in
Australia [15].
Thus, the diagnosis and management of borderline
vitamin B12 deficiency within general practice is
shrouded by uncertainty and variable between practi-
tioners. Requests for B12 testing have grown rapidly.
Between 2003-2004 and 2013-2014, claims for tests in
Australia measuring serum B12 or red cell folate (and
serum folate if required) increased by 119% [16]. The
most common reasons for requesting tests were mac-
rocytic anaemia, neurological symptoms and screen-
ing [17–19].
In contrast, there is no existing literature on the rea-
sons for initiating vitamin B12 supplementation. An
earlier qualitative study conducted by the authors
revealed five sub-themes which summarised the opin-
ions and attitudes of GPs on borderline vitamin B12
deficiency [20]. Overall GPs emphasised on the lack of
quality post-graduate teaching, pressures to prescribe
from patients and differing views between colleagues
on how deficiency should be managed. Further
research on these sub-themes may elicit interesting
findings on why supplementation is initiated. This will
help to inform GPs on their management and may
lead to better patient health outcomes.
This study aims to identify factors which correlate
to the propensity of GPs to prescribe supplementation,
either as intramuscular injections or in oral form, for
borderline vitamin B12 deficiency. We define
borderline deficiency as a situation where the GP is
uncertain if the patient has a clinically relevant B12
deficiency that should be substituted. We hypothesise
that GPs who are more receptive to patient demands
correlate with an increased propensity to prescribe
B12 supplementation.
Methods
The study was approved by the Human Research
Ethics Committee at James Cook University under the
ethics approval number H6476.
Survey construction
The survey was composed of four parts: demographic
information, agreement with constructed statements,
approach to a case of borderline B12 deficiency, and
when education on deficiency was last received.
Participants were required to indicate their age, gen-
der, year of graduation, and level of GP training, but
otherwise remained anonymous.
Survey statements and a Likert scale asserting the
level of agreement were constructed for the purpose
of this study. Statements were based on sub-themes
identified in an earlier qualitative study conducted
by the authors [20]. The 5-point Likert response scale
was employed for the statements and case study,
where 1¼ strongly disagree, 2¼disagree, 3¼ neutral,
4¼ agree, and 5¼ strongly agree. ‘Neutral’ was
retained as an option for participants to select if they
felt ambivalent towards a statement, as would be
expected for this topic.
A hypothetical case was formulated from the expe-
riences described by participants in an earlier qualita-
tive study: “An 80 year old lady presents with a one
year history of fatigue as her sole symptom and a
serum B12 level of 195 pmol/L. Physical examination
and other pathology results are within normal limits.
She takes a short daily walk and has a decent diet.”
The practitioner was asked if they would request com-
plementary biomarkers, initiate vitamin B12 supple-
mentation, provide further dietary recommendations
or retest in 3-12 months.
With regards to when education was last received,
a scale was employed with the options of “more than
10 years ago”, “last 10 years”, “last 3 years”, “last 12
months”, and “last 6 months”. The survey was carefully
discussed and revised several times by GC and RG
before the final version.
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Data collection
The study population consisted of practicing GPs who
were in the Cairns and Atherton Tablelands region in
Australia between July and August 2016. Participants
were recruited in one of three settings: conferences
held in Cairns, Palm Cove and Mt Isa (three occasions),
GP registrar educational meetings in Atherton (two
occasions), and booked lunch time meetings with indi-
vidual general practices (20 practices). Surveys were
individually numbered for tracking distribution, return
and to finally estimate the response rate. These were
hand-delivered with information sheets on each occa-
sion, but one, by GC. A total of 15 surveys were dis-
tributed, and returned, at a conference in Mt Isa by
one volunteering participant. Surveys that had been
distributed to practice managers at conferences or left
at general practices were followed-up by phone after
two weeks, and reminded again one week later.
Beyond this timeframe, surveys were marked as
unreturned.
Data analysis
Responses were exported to IBM SPSS Statistics v24
for Windows for statistical data analysis. All variables
were recoded to have binary outcomes. For the Likert
scale statements, responses marked as ‘strongly dis-
agree, ‘disagree’ or ‘neutral’ were coded as 0, and the
responses ‘agree’ and ‘strongly agree’ were coded
as 1. For the other scale, education received further
back in time than three years was coded as 0, and
those within the last three years as a 1. By univariate
binary logistic regression, prescription of B12 supple-
ments was analysed as a dependent variable against
each other statement. Variables with a level of signifi-
cance equal or below 0.2 were then taken to multivari-
ate backward stepwise logistic regression. The same
process was repeated with the requesting of comple-
mentary biomarkers as the dependent variable. The
univariate regression was merely used as a sorting
mechanism and not considered as a result.
Sample size calculation
Male medical practitioners have in other situations
been seen as more proactive (for better or worse)
than female medical practitioners in prescribing
behaviour [21]. The authors wanted to explore if this
was also true for the prescribing of vitamin B12 sup-
plementation for the described scenario. We assumed
that 30% of female and 60% of male practitioners are
high prescribers of B12 and using logistic regression.
Level of significance was set to 0.05 and power set to
80%. A required sample size of 88 GPs was calculated
by the statistical power analysis program GPower,
version 3.1.9.2, on 31st October, 2014. We aimed to
collect more than 90 surveys.
Results
During the seven weeks of data collection from July to
August 2016, a total of 144 surveys were distributed
and 128 (89%) were returned. There were 99 (77%)
fully completed and 29 (23%) partially completed sur-
veys. The majority of surveys were returned in person
(n¼ 109, 85%) and 19 were returned by e-mail (15%).
Participant demographics
Participants’ ages ranged from 26 to 72 years. Of the
group, 46% (n¼ 59) were female, 52% (n¼ 67) were
male and two participants did not disclose gender. GP
specialists made up 63% of participants (n¼ 80).
Distribution of responses
The majority (63%, n¼ 80) of participants indicated they
commonly see patients with vitamin B12 deficiency
(Table 1). There was a wide spread of responses towards
the influence of colleagues’ practice, and towards
Table 1. Responses to statements on borderline B12 deficiency.
Survey Statements n Strongly Disagree Disagree Neutral Agree Strongly Agree
I commonly see patients with vitamin B12 deficiency 128 6 23 19 69 11
By discussion or through patient notes, I observe how
colleagues manage cases of vitamin B12 deficiency and
imitate them
126 9 34 33 46 4
Patient demands influence my management of borderline
vitamin B12 deficiency
128 9 40 38 37 4
There is currently an overuse of vitamin B12 in Australia 127 3 17 54 38 15
I advocate injections over oral therapy in patients who
require vitamin B12 treatment and have known
malabsorption
128 3 8 9 67 41
I often request for complementary biomarkers (methylma-
lonic acid, homocysteine) prior to diagnosing and
treating for vitamin B12 deficiency
128 20 64 23 15 6
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patient demands, with almost equal numbers on either
side of neutral in both cases (number in disagreement
to number in agreement were 43:50 and 49:41, respect-
ively). However, participants generally inclined towards
agreement with their colleagues’ practice, and disagree-
ment in response to patients’ preferences. A large pro-
portion (42%, n¼ 54) of participants were neutral to the
statement on the overuse of vitamin B12 in Australia.
The vast majority of participants (84%, n¼ 108) agreed
with the statement that in cases of known malabsorp-
tion, injections were advocated over oral therapy.
Complementary biomarkers, defined here as either
methylmalonic acid or total homocysteine, were often
requested by 16% of participants (n¼ 21).
In relation to the hypothetical case of borderline
B12 deficiency (Table 2), participants were largely sup-
portive of commencing B12 supplementation (51%,
n¼ 60), providing dietary advice (79%, n¼ 97) and re-
testing levels on follow-up (89%, n¼ 109). A large pro-
portion (44%, n¼ 54) of participants were disinclined
to requesting any additional biomarkers; however 24%
(n¼ 29) of participants also felt ambivalent towards
the statement. It was noted that the statement to
‘recommend or initiate vitamin B12 supplementation’
had the lowest frequency of responses (n¼ 117).
A total of 56 participants (44%) received some
form of formal teaching on vitamin B12 deficiency
within the last three years. For 28 participants (22%),
teaching on the topic was more than ten years ago.
Propensity to request biomarkers or prescribe B12
By univariate analysis with the initiation of B12 supple-
mentation as the dependent variable, three independent
variables were found to have a p-value of less than 0.2
(Table 3). Two variables remained statistically significant
on multivariate analysis: an agreement that patient
demands influence the management of borderline vita-
min B12 deficiency (p¼ 0.037), and belief in an overuse
of vitamin B12 in Australia (p¼ 0.019).
With the requesting of complementary biomarkers
as the dependent variable, three different independent
variables were identified with a p-value of less than
0.2 (Table 4). Two variables remained on multivariate
analysis: participants who commonly see patients with
vitamin B12 deficiency (p¼ 0.045), and age of the par-
ticipants (p¼ 0.070).
Discussion
Summary of main findings
The present study identified factors which correlate to
GPs’ propensity to prescribe for borderline vitamin B12
deficiency. Practitioners who were more receptive to
patient demands were found to be more likely to pre-
scribe B12 supplementation than their counterparts.
Meanwhile, practitioners who perceived there to be an
overuse of B12 supplementation in Australia were less
likely to prescribe. The use of complementary bio-
markers prior to diagnosing or treating for deficiency
was limited amongst participants. The present study
found that GPs who commonly see patients with vita-
min B12 deficiency were less likely to submit requests
for complementary biomarkers.
Being the patient’s or the society’s doctor
Our study findings echo the major theme of
‘Balancing’ described by Hansson et al. in their
Table 2. Responses to hypothetical case of borderline B12 deficiency.
Survey Statements n Strongly Disagree Disagree Neutral Agree Strongly Agree
Request complementary biomarkers 123 16 38 29 35 5
Recommend or initiate vitamin B12 supplementation 117 8 25 24 54 6
Provide further dietary recommendations 123 3 12 11 79 18
Retest in 3 – 12 months 123 3 7 4 88 21
Table 3. Factors correlating to the propensity to prescribe B12 supplementation.
Univariate (unadjusted) logistic regression
Step-wise multivariate (adjusted)
logistic regression (n¼ 114)
n p value OR (95% CI) p value OR (95% CI)
Increasing age of GP (decades) 115 0.88 0.97 (0.70 – 1.4)
Male Gender 115 0.11 0.55 (0.26 – 1.1)
GP Trainee 109 0.21 1.7 (0.75 – 3.7)
Commonly sees B12 deficiency 117 0.24 1.6 (0.73 – 3.3)
Influenced by colleagues 115 0.45 1.3 (0.63 – 2.8)
Influenced by patients 117 0.052 2.2 (0.99 – 4.8) 0.037 2.4 (1.1 – 5.7)
Perceives overuse 116 0.029 0.43 (0.20 – 0.92) 0.019 0.39 (0.18 – 0.86)
Advocates injections 117 0.53 1.4 (0.50 – 3.8)
Requests biomarkers 117 0.69 1.2 (0.45 – 3.4)
Last B12 education <3 years ago 115 0.75 1.1 (0.54 – 2.4)
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descriptive, interview-based study conducted in 2007
[22]. In the present study, GPs who are receptive to
patient demands for testing or treatment are more
likely to initiate B12 supplementation. We interpret
this finding as GPs prescribing in the interest of the
patient. Conversely, participants who felt there is an
overuse of B12 supplementation were, almost to the
same degree, less likely to prescribe. These GPs appear
to place a greater emphasis on the potential impact of
prescription to the wider community.
The continuous struggle of finding a balance
between being the personal doctor and the society’s
doctor is described by Hansson et al. as a source of
inner conflict. Due to the nature of primary health care,
GPs are in a unique position where they can develop
very strong, continuous doctor-patient relationships. At
the same time, there is also a sense of duty that has to
be upheld towards society. It is not known whether
vitamin B12 testing is cost-effective, as no economic
analyses on the subject have been conducted [16].
However, testing on the national scale has rapidly
increased in recent years, and repeated testing for pre-
viously indeterminate results could lead to financial
costs and anxiety to the patient. These considerations
need to be weighed with respect to patients’ wishes,
and thus GPs have to find a balance between these
opposing conditions. In the absence of guidelines with
a strong evidence base, GPs need to be aware of how
their prescribing propensity may be affected by their
acceptance and response to these roles.
Complementary biomarkers
Study participants were generally disinclined or felt
ambivalent towards the use of complementary bio-
markers prior to diagnosing and managing borderline
vitamin B12 deficiency. The association was statistically
significant for GPs who regularly saw patients with
vitamin B12 deficiency. We propose two explanations
for this finding. Firstly, these GPs see patients with
more severe clinical manifestations of deficiency and
therefore warrant immediate supplementation, even if
serum B12 levels are within normal limits or the inde-
terminate range [14]. Secondly, GPs who regularly see
patients on the spectrum of deficiency are more famil-
iar with the limitations around complementary tests.
Although plasma methylmalonic acid is commonly
used overseas as a second-line investigation to clarify
uncertainties, the test has not been found to be diag-
nostically accurate and also incurs a cost in Australia,
making it less used [14,23].
Furthermore, GPs’ adherence to guidelines varies. In
a recent qualitative meta-analysis, GPs’ attitudes and
adherence to guidelines were found to be systematic-
ally influenced by whether the guideline of interest is
prescriptive or proscriptive. Guidelines were not
believed to be flexible enough or to accurately reflect
the complexity of individual cases [24]. Thus, despite
international recommendations, local GPs may con-
tinue to doubt the value of complementary tests.
Existing literature suggest increasing age is associ-
ated with lower rates of pathology ordering [25]. In
contrast, our study found the propensity to request
complementary biomarkers appeared to increase with
respect to age. Although the p value was 0.07, this is
potentially interesting. One possible explanation may
be that older GPs have spent more years in clinical
practice and have experienced more missed cases of
borderline B12 deficiency (where patients later became
symptomatic) that they now want to identify with the
newer complementary tests.
Study strengths
The present study achieved a response rate of 89%,
which is high for GP surveys. This is in contrast to the
average response rate of 61% (95% CI 59-63%) for pos-
tal surveys [26]. Brodaty et al. outline time as the main
barrier to GP participation [27]. As such, to avoid this
barrier commonly found with postal or online distribu-
tion, a decision was made to hand deliver and collect
surveys in-person. Survey statements were designed
Table 4. Factors correlating to the propensity to request complementary biomarkers.
Univariate (unadjusted) logistic regression
Step-wise multivariate (adjusted)
logistic regression (n¼ 112)
n p value OR (95% CI) p value OR (95% CI)
Increasing age of GP (decades) 121 0.19 1.3 (0.90 – 1.8) 0.070 1.4 (0.97 – 2.1)
Male Gender 121 0.72 1.1 (0.53 – 2.5)
GP Trainee 114 0.15 0.51 (0.21 – 1.3)
Commonly sees B12 deficiency 123 0.11 0.53 (0.25 – 1.2) 0.045 0.41 (0.17 – 0.98)
Influenced by colleagues 121 0.66 1.2 (0.55 – 2.6)
Influenced by patients 123 0.68 1.2 (0.53 – 2.6)
Perceives overuse 122 0.25 1.6 (0.73 – 3.3)
Advocates injections 123 0.53 0.72 (0.26 – 2.0)
Last B12 education <3 years ago 121 0.57 1.3 (0.58 – 2.7)
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from the results of a qualitative study previously con-
ducted by the same authors. Data collected from the
quantitative part were thus more likely to reveal sig-
nificant information that may confirm the opinions
and attitudes revealed in the qualitative study.
Study limitations
Due to the indiscriminate recruiting of GPs at confer-
ences, our study is not representative of all GPs who
practice in the Cairns and Atherton Tablelands region,
Australia. However, this was a deliberate decision
made to encourage participation in the study.
Although surveys were hand-delivered so questions
could be clarified at the scene, there is still a possibil-
ity that participants may have experienced some con-
fusion over the wording or meaning of the
statements, but chose to not verbalise this confusion.
Application and future research
To our knowledge, this study is the first to examine
factors correlating to GPs’ prescribing propensity of
supplementation for borderline vitamin B12 deficiency.
As outlined in the preceding qualitative research, GPs
are often unaware of how colleagues practice, but at
the same time, use colleagues’ documentation as a
comparative marker to determine the appropriateness
of their management [20]. The present study findings
enable GPs to compare and actively reflect on their
prescribing behaviour towards vitamin B12 supple-
mentation. Similar research to this study can be con-
ducted with GPs in other regions of Australia or
overseas to confirm the present study’s findings.
Conclusion
Borderline vitamin B12 deficiency is common amongst
patients who present to general practice. The ability to
recognise, diagnose and treat for deficiency however,
is variable between GPs. When faced with borderline
vitamin B12 deficiency, GPs were largely agreeable
with initiating supplementation, providing dietary
advice and re-testing serum vitamin B12 levels on fol-
low-up. The identified disparity to prescribe vitamin
B12 for borderline deficiency may be described as an
attempt in the GP collective to seek a balance
between being the patient’s or the society’s doctor.
We propose that relevant authorities try to reduce
this disparity by proposing a guideline for managing
patients with borderline vitamin B12 deficiency. Ideally
there would agreement upon both the upper limit of
serum B12 levels where neither treatment nor
complementary testing are indicated, and lower limit
of B12 where treatment is indicated without comple-
mentary testing. Recommendations should also be
made for managing patients with levels in-between
the cut-off values, perhaps driven by the presenting
symptom. The guideline should then be validated in a
separate study to assess the predictive values of the
different cut-offs. Public funding would be essential to
the development of this guideline however, as
pharmaceutical companies are unlikely to give priority
to vitamin B12 since it is a naturally occurring
biomolecule.
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